Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253550 · ClinicalTrials.gov registry record · Phase 2
Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection
A Phase 2 study, sponsored by Peter J. Ruane, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02253550: Completed Phase 2 study, sponsored by Peter J. Ruane, M.D..
NCT02253550 is a Phase 2 study that has completed, run by Peter J. Ruane, M.D.. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02253550, a Phase 2 study, has completed, sponsored by Peter J. Ruane, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.
Primary Outcome
HCV RNA will be measured 12 weeks post-treatment to evaluate SVR
Interventions
- DRUG Sofosbuvir
- DRUG Simeprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT02253550 record still lists
NCT02253550 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Sofosbuvir is the first listed.
NCT02253550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02253550 about?
NCT02253550 is a clinical study titled "Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection". This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.
What is the current status of trial NCT02253550?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02253550?
The interventions under investigation include: Sofosbuvir (DRUG), Simeprevir (DRUG).
Who is sponsoring clinical trial NCT02253550?
This trial is sponsored by Peter J. Ruane, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02253550's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia